EUCTR2011-001287-22-IT
Active, not recruiting
Not Applicable
A Prospective Randomized Crossover trial of Oral Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Patients with CPVT and ICD
- Sponsor
- FONDAZIONE SALVATORE MAUGERI - CLINICA DEL LAVORO E DELLA RIABILITAZIONE
- Status
- Active, not recruiting
- Last Updated
- 12 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- Clinical diagnosis of CPVT, based on: reproducible polymorphic or bidirectional ventricular tachycardia with exercise or Ventricular ectopy on exercise test with RYR2 or CASQ2 mutation \- Functioning ICD in place \- On stable dose of standard therapy defined as the maximal tolerated dose of beta\-blocker and may include a calcium channel blocker (Patients on flecainide or mexiletine are also eligible for enrollment after a 1 week washout” period during which flecainide or mexiletine is discontinued, and standard therapy alone is used).
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 0
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 10
- •F.1\.3 Elderly (\>\=65 years) no
- •F.1\.3\.1 Number of subjects for this age range
Exclusion Criteria
- •Females who are pregnant or plan to be pregnant during the study period • Children \< 5 years of age • Patients unable to perform treadmill exercise • Patients with significant structural heart disease • Patients with features consistent with Andersen\-Tawil syndrome • Patients with known hypersensitivity to flecainide • Patients on amiodarone • Patients not expected to comply with follow\-up
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 2
To study the effectiveness of Tablet Fluuconazole in superficial fungal infection (Tinea Corporis)CTRI/2020/05/025442Dr ASVINI J
Completed
Not Applicable
Oral mandibular advancement devices for obstructive sleep apnoea-hypopnoeaObstructive sleep apnoeaNervous System DiseasesSleep disordersISRCTN02309506Papworth Hospital NHS Foundation Trust (UK)90
Recruiting
Not Applicable
A Prospective Randomized Controlled Study of Oral Tranexamic Acid for Prevention of Postinflammatory Hyperpigmentation after Q-Switched Nd-YAG (532 nm) Lasersolar lentiginespost inflammatory hyperpigmentationsolar lentiginespost inflammatory hyperpigmentationTCTR20161010004Division of Dermatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital40
Active, not recruiting
Phase 1
A clinical trial into the relief of breathlessness in patients with heart failure by inhaling furosemide which is usually taken as a tablet or injection.Advanced heart failure with reduced ejection fraction (less than or equal to 40%) with significant breathlessness that limits what they are able to do. MRC Dyspnoea Scale =2.MedDRA version: 20.0Level: LLTClassification code 10008908Term: Chronic heart failureSystem Organ Class: 100000004849Therapeutic area: Body processes [G] - Circulatory and Respiratory Physiological Phenomena [G09]EUCTR2017-000124-95-GBniversity of Oxford30
Active, not recruiting
Phase 1
Crossover and randomized clinical trial on the effect of Resincolestiramine in the intestinal absorption of new uremic toxins in patients in hemodialysis with chronic renal insufficiencyChronic renal insufficiencyTherapeutic area: Body processes [G] - Physiological processes [G07]EUCTR2017-001899-32-ESDr. Abelardo Aguilera Peralta58